Skip to main content
. 2017 May 15;2017(5):CD011673. doi: 10.1002/14651858.CD011673.pub2

Comparison 3.

Interferon (IFN‐α) alone versus IFN‐α plus bevacizumab in first‐line therapy of metastatic renal cell carcinoma

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 1‐year mortality 2 1381 Risk Ratio (M‐H, Random, 95% CI) 1.17 [1.00, 1.36]
2 Overall survival 2 Hazard Ratio (Random, 95% CI) 1.13 [1.00, 1.28]
3 Adverse events (grade ≥ 3) 2 1350 Risk Ratio (M‐H, Random, 95% CI) 0.77 [0.71, 0.84]
4 Progression‐free survival 2 Hazard Ratio (Random, 95% CI) 1.53 [1.36, 1.73]
5 Tumour remission 2 1205 Risk Ratio (M‐H, Random, 95% CI) 0.39 [0.31, 0.50]